mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis by Yu, Xinhua et al.
mtDNA nt13708A Variant Increases the Risk of Multiple
Sclerosis
Xinhua Yu1, Dirk Koczan2, Anna-Maija Sulonen3, Denis A. Akkad4, Antje Kroner5, Manuel Comabella6,
Gianna Costa7, Daniela Corongiu7, Robert Goertsches2, Montserrat Camina-Tato6, Hans-Juergen
Thiesen2, Harald I. Nyland8,9, Sverre J. Mørk10, Xavier Montalban6, Peter Rieckmann5, Maria G. Marrosu7,
Kjell-Morten Myhr8,9, Joerg T. Epplen4, Janna Saarela3, Saleh M. Ibrahim1*
1 Section of Immunogenetics, University of Rostock, Rostock, Germany, 2Department of Immunology, University of Rostock, Rostock, Germany, 3Department of
Molecular Medicine, National Public Health Institute, Helsinki, Finland, 4Department of Human Genetics, Ruhr University, International Graduate School of Neuroscience
(IGSN), Bochum, Germany, 5Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wu¨rzburg, Wu¨zburg, Germany,
6Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain, 7 The Centro Sclerosi Multipla,
Dipartimento di Scienze Cardiovascolari e Neurologiche, University of Cagliari, Cagliari, Italy, 8Department of Neurology, Haukeland University Hospital, University of
Bergen, Bergen, Norway, 9Department of Clinical Medicine, University of Bergen, Bergen, Norway, 10Department of Pathology, Haukeland University Hospital, Gade’s
Institute, University of Bergen, Bergen, Norway
Abstract
Background: Mitochondrial DNA (mtDNA) polymorphism is a possible factor contributing to the maternal parent-of-origin
effect in multiple sclerosis (MS) susceptibility.
Methods and Findings: In order to investigate the role of mtDNA variations in MS, we investigated six European MS case-
control cohorts comprising .5,000 individuals. Three well matched cohorts were genotyped with seven common,
potentially functional mtDNA single nucleotide polymorphisms (SNPs). A SNP, nt13708 G/A, was significantly associated
with MS susceptibility in all three cohorts. The nt13708A allele was associated with an increased risk of MS (OR= 1.71, 95% CI
1.28–2.26, P= 0.0002). Subsequent sequencing of the mtDNA of 50 individuals revealed that the nt13708 itself, rather than
SNPs linked to it, was responsible for the association. However, the association of nt13708 G/A with MS was not significant
in MS cohorts which were not well case-control matched, indicating that the significance of association was affected by the
population structure of controls.
Conclusions: Taken together, our finding identified the nt13708A variant as a susceptibility allele to MS, which could
contribute to defining the role of the mitochondrial genome in MS pathogenesis.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory neurodegen-
erative disease that affects the central nervous system in genetically
susceptible individuals. The mitochondrial genome (mtDNA) has
been suggested to be involved in MS development for several
reasons. First, mtDNA variations play an important role in
neurodegenerative diseases, with deleterious mtDNA mutations
causing early onset neurodegenerative disorders, and common
mtDNA polymorphisms are associated with late-onset neurode-
generative disorders [1–5]. Secondly, Lebers hereditary optic
neuropathy (LHON), a disease caused by mtDNA mutations,
includes symptoms of inflammatory demyelination similar to MS
[6]. Those observations suggest that mtDNA could play a role in
pathogenesis of MS. This hypothesis is also supported by the
observations from two family-based half-sibling studies, suggesting
that there is a maternal parental-of-origin effect in MS [7,8]. The
search for the mtDNA variations contributing to MS started about
a decade ago [9,10], and most studies focused on the LHON
mutations. The consensus is that the LHON primary mutations
are not associated with MS [11]. LHON secondary mutations,
such as nt4216 and nt13708, and their related haplogroup J,
however, were suggested to be associated with MS [10,12–14]. But
because of the small number of samples used, these associations
are rather weak or even debatable [9,11,14].
A common difficulty in investigating the role of mtDNA in
polygenetic diseases is that it is challenging to precisely define the
susceptibility SNP. Since human mtDNA is characterized by
maternal transmission and a lack of recombination, it always exist
in haplotype forms [15]. Therefore, associations between mtDNA
polymorphisms and polygenic diseases are always identified as
associations between mtDNA haplotypes and diseases, making it
challenging to precisely define the mtDNA polymorphism
contributing to diseases[5,16]. There could be two solutions to
this. One is to evaluate the association between each mtDNA
polymorphism on the haplotype and the disease. This method is
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powerful but extremely resource-consuming. The second method
is much less resource consuming but is only suitable for some
cases. That is, when two related mtDNA haplotypes were
associated with the same diseases, to check the mtDNA
polymorphism(s) shared by these two haplotypes. Nevertheless,
for both methods, a large number of samples are required.
In this study, we collected six European MS cohorts comprising
.2,500 sporadic cases and a similar number of healthy controls.
The aim of this study is twofold. The first one is to investigate
whether the mtDNA polymorphisms or haplotypes are associated
with the susceptibility to MS. Secondly, if there is an association,
we attempt to identify the susceptibility mtDNA polymorphism
using this larger number samples.
Results
nt13708 G/A is associated with susceptibility to MS
Previously, a maternal parent-of origin effect was observed in a
large half-sibling study in MS family [8]. This suggests a role of
mtDNA variations in MS, and the susceptibility variation could be a
common mtDNA polymorphism. Based on this, we selected seven
potentially functional common mtDNA polymorphisms with fre-
quencies of more than 3%. In addition, the three Caucasian mtDNA
haplogroups, J, K, and I, that are related to polygenic diseases, could
be constructed with these seven SNPs [16]. We collected six
European MS cohorts containing,5,000 samples. In the initial part
of the study, we genotyped seven mtDNA polymorphisms in three
well matched cohorts, in terms of both age and geography. The
frequencies of nt13708 minor allele, A, were significantly higher in
MS cases than in controls in all three cohorts, with OR values of 1.63
to 1.82. Meta-analysis of the combined cohorts showed that
nt13708A variant was significantly associated with an increased risk
to MS (OR=1.71, 95% CI 1.29–2.27, P=0.0002). The six other
SNPs were not associated with MS (Table 1). Three European
mtDNA haplogroups could be constructed with the seven SNPs used
in this study according to Torroni et al [17,18], including
haplogroups I, J andK. The frequency of haplogroup J, a haplogroup
constructed with nt10398 and nt13708 SNPs, was higher inMS cases
than in controls (OR=1.53, 95% CI 1.13–2.09, P=0.007), with the
same tendency in all three cohorts. Haplotype I and K were not
associated with MS (Table 1).
nt13708 G/A is the variation responsible for the
association
The nt13708A allele was reported to be linked to nt10398G and
nt4216C alleles and regarded as a tag-SNP of the haplogroup J
[17,18]. In this study, we observed that most of the nt13708A
alleles were linked to the nt10398A and nt4216C alleles (,85%).
However, a small proportion of nt13708A alleles (,15%) were
not. Thus, the mtDNA carrying nt13708A allele could be divided
into two haplotypes, nt13708A-nt4216C (haplogroup J) and
nt13708A-nt4216T. We then determined whether the both
haplotypes are associated with MS. Both haplotypes, nt13708A-
nt4216C (OR=1.60, 95% CI 1.18–2.17, P=0.00349) and
nt13708A-nt4216T (OR=2.39, 95% CI 1.22–4.72, P=0.014)
significantly increased the risk of MS as compared to the wildtype
haplotype, nt13708G-nt4216T. (Figure 1A).
The two disease associated mtDNA haplotypes make it possible
to identify the SNP responsible for the association by checking the
variation(s) shared by then. We subsequently sequenced the
complete mitochondrial genome of 50 individuals, containing 24
samples with nt13708A-nt4216C, 23 samples with nt13708A-
nt4216T and three samples with nt13708G. Samples were
randomly selected from patients and controls. The phylogenetic
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analysis showed that samples with nt13708A-nt4216C and
nt13708A-nt4216T haplotypes formed two distinct branch on
the phylogenetic tree, indicating that they are differed from each
other considerably (Figure 1B). We then checked overlap variants
shared by both haplotypes. Although a few polymorphisms, e.g.
nt2706 A/G and nt7028 C/T, carrying by one haplotype also
existed in several cases of the other haplotype, the only SNP
shared by the two susceptibility haplotypes was nt13708 G/A
(Table 2). Therefore, nt13708 G/A, rather than an SNP linked to
it, was the polymorphism contributing to the susceptibility to MS.
The association is not significant in non-well matched
cohorts
We then investigated the association of nt13708A variant withMS
in other three European cohorts which were not case-control well
matched, in terms of the age or geography (Table 3). However, no
significant association was observed (Table 4). Previous studies
showed that the frequency of nt13708A variant (haplogroup J) was
associated with age, with higher frequency in centenarians than in
younger individuals[19,20]. Also, its frequency varied considerably
among populations [5,9,14,21–24]. We proposed that the lack of
significant association was due to the difference between cases and
controls in age or geographic origin.
To test this, we performed further analysis with the large Finnish
cohort by stratifying the samples. All samples were classified into two
groups according to the geographic origin. Finland I group
contained samples from the Southern Ostrobothnia region where
the incidence of MS is higher than other Finnish regions [25], and
Finland II group contained samples from other regions. In each
geographic group, controls were further stratified into two group
according to age. Indeed, when we classified the cohort, we observed
that the frequency of nt13708A variant was affected by, both, age
and geographic origin. The frequency of the nt13708A variant was
higher in the Finland I cohort than in the Finland II cohort (7.1% vs.
5.1% in control and 10.2% vs. 5.9% in patients). Also, the frequency
of nt13708A was associated with age, with lower frequency in
unrelated controls than their fathers in Finland II cohort (3.3% vs.
5.5%). When using the younger, unrelated, geographically matched
controls, the odds ratio increased to 1.84 which was similar to those
three well matched MS cohorts (Table 5). Although the association
was still not significant because of the small number of samples after
stratification, this suggests that association of nt13708 G/A with MS
could be affected by the population structure of the cohort.
Discussion
In this study, we identified an association between nt13708 G/A
polymorphism and susceptibility to MS, which was consistent with
previous results [10,12]. By sequencing mtDNA of samples with
two disease association haplotypes, we demonstrated that
nt13708A variant was responsible for the increase of the risk of
MS. To our knowledge, this is the first time to identify a casual
variation on mtDNA predisposing polygenic disease in human.
This precise identification will help in exploring the molecular
mechanisms of pathogenesis of MS. Also, since the nt13708 G/A
polymorphism is a tag-SNP of haplogroup J which has been
reported to be associated with other complex clinical traits, e.g.
increasing the risk of type 2 diabetes and longevity [20,24], it is
reasonable to speculate that nt13708A variant might be respon-
sible for the effect.
The nt13708 G/A SNP is located in the mt-ND5 gene. It results in
an amino acid substitution of A to T at a moderately conserved
region. A recent study investigating the functions of the nt4216 T/C
and nt13708 G/A mutations revealed that they do not further
impair in vivo mitochondrial oxidative metabolism when linked woth
the primary LHON mutation nt11778 [26]. However, the function
of the nt13708 G/A itself has not been investigated. Given the role of
nt13708A in the MS, investigating the function of this common
variant which will help to elucidate the pathogenesis of the disease.
In the future, we plan to approach this aim using two strategies. First,
study the mitochondrial performance in large numbers of patients
and controls to compensate for the genetic heterogeneity. The
second strategy is using mouse model. Since most mouse classic
inbred strains (CIS) were descended from a single female and
mtDNA mutation are common in CIS, it is possible to identify
strains whose mtDNAs differ from each other only in a mt-ND5
mutation [27]. Thereafter, conplastic strains for such mutation could
be generated and used to investigate the role of the mt-ND5 in
mouse models of MS.
Figure 1. Two mtDNA haplotypes associated with MS. (A)
Evaluation of the association between four mtDNA haplotypes and MS.
The four haplotypes were constructed with nt13708 G/A and nt4216 T/
C polymorphisms. The association was evaluated using the wildtype
haplotype (nt13708G-nt4216T) as the control genotype, and Odds
ratios and P values of the other three haplotypes were determined. (B)
Phylogenetic tree of the two disease-associated mtDNA hyplotypes.
The phylogenetic tree were constructed base on the mtDNA sequence
of 24 sample with nt13708A-nt4216C (sample A1–A24) and 23 samples
with nt13708A-nt4216T (sample B1–B23) using ClusterW softeware.
doi:10.1371/journal.pone.0001530.g001
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Although the mechanism underlying the effect of nt13708A
variant on MS is still unclear, several recent publications
demonstrating the association of MS or its animal model with
mitochondrial genes e.g. uncoupling protein 2 (UCP2) suggest a
potential mechanism. UCP2 is located in the mitochondrial inner
membrane and uncouples the protons generated during oxidative
phosphorylation (OXPHOS) [28]. UCP2 has been reported to
play a role in MS and its animal model, Experimental
Autoimmune Encephalomyelitis (EAE), and its role in affecting
reactive oxygen species (ROS) production in mitochondria has
been proposed to be a potential mechanism [28–30]. Therefore, it
is conceivable that mt-ND5 nt13708A variant might increase the
susceptibility to MS by affecting the mitochondrial ROS
production.
It is noteworthy to mention the heterogeneity in the significance
of the association of nt13708 G/A polymorphism with MS. Such
heterogeneity was also observed among previous studies with
relative small number of the samples [9,10,12]. However, due to
the small sample size, this heterogeneity could not be evaluated
genetically. In this study, with a large sample size in Finnish
cohort, we showed that age and geographic origin of controls
could be the reason for the heterogeneity. The frequency of
nt13708A variant or J haplogroup have be reported to be
associated with aging in Finnish and Sardinian population
observations, with higher frequency in the older than the younger
people [19,20]. This was confirmed in our study in both Finland II
cohort (5.5% vs 3.3%) and Sardinia cohort (13.4% vs 7.8%
[20,23]). Therefore, when the controls are considerably older then
the cases, the significance of the association between nt13708 G/A
and MS will be reduced. Also, we observed that the frequency of
the nt13708A variant is associated with geographic origin in the
Finnish cohort. The frequency of the nt13708A variant was higher
in the Southern Ostrobothnia region where the prevalence of MS
disease is comparatively high [23,25] than in the rest of Finland.
Thus, when samples are collected from different geographic
origins that differ from each other in the frequency of nt13708A
variant, the significance of the association will be affected.
Since the nt13708 G/A variation seems to play a role in the
susceptibility to MS and perhaps also in other complex diseases, it
is important to consider ethnicities. A summary of the prevalence
Table 2. mtDNA variations linked to in nt13708A variant
Variations* Gene
Frequency in
haplotype
nt13708A-
nt4216C
Frequency in
haplotype
nt13708A-
nt4216T
73 a/g Control region 14/24 4/23
185 g/a Control region 7/24 0/23
195 t/c Control region 6/24 5/23
228 g/a Control region 12/24 0/23
295 c/t Control region 23/24 0/23
489 t/c Control region 23/24 0/23
1438 g/a 12S rRNA 0/24 9/23
2706 a/g 16S rRNA 23/24 7/23
3010 g/a 16S rRNA 19/24 3/23
4216 t/c Mt-ND1 Y-H 24/24 0/23
4769 g/a Mt-ND2 syn 0/24 9/23
7028 c/t Mt-COI syn 23/24 7/23
10398 a/g Mt-ND3 T-A 23/24 0/23
11251a/g Mt-ND4 syn 23/24 0/23
11719 g/a Mt-ND4 syn 23/24 4/23
12612 a/g Mt-ND5 syn 23/24 0/23
13708 g/a Mt-ND5 A-T 24/24 23/23
14766 c/t Mt-CYB T-I 23/24 4/23
14798 t/c Mt-CYB F-L 17/24 0/23
15452 c/t Mt-CYB L-I 23/24 0/23
16069 c/t Control region 23/24 0/23
16126 t/c Control region 23/24 0/23
16519 t/c Control region 1/24 9/23
*Positions of variations are according to the reference sequence J01415. Only
those variations with frequencies of more than 20% in the total 50 sequenced
samples are presented.
doi:10.1371/journal.pone.0001530.t002
Table 3. Population demographics of the non-well matched MS cohorts
Cohorts Patients Controls
Number Age (mean6SD) Location Number Age (mean6SD) Location Composition
Finland j 936 42.9610.0 Finland 970 63.16 12.4 f* Finland Unrelated controls
Father of controls
Father of patients
Germany II 342 38.1610.5 Bochum 371 43.7612.4 Essen Unrelated controls
Sardinia 194 37.8610.2 Sardinia 194 62.5615.5* Sardinia Father of the patient
jThe samples of the Finnish cohort have been collected from five university and central hospitals around Finland (Helsinki, Tampere, Seina¨joki, Kuopio, Oulu).
f, calculated from 700 samples with age infomation.
*, significantly higher than patients.
doi:10.1371/journal.pone.0001530.t003
Table 4. Non-significant association of nt13708A variant with
MS in three cohorts
Frequency OR (95% CI)
Patient Control
Finland*1 0.068 (n = 936) 0.059 (n = 980) 1.18 (0.75–1.95)
Germany II1 0.137 (n = 342) 0.132 (n = 371) 1.04 (0.67–1.61)
Sardinian* 0.165 (n = 194) 0.134 (n = 194) 1.27 (0.72–2.23)
*cases and controls are not age matched and
1cases and controls are not geographic matched.
doi:10.1371/journal.pone.0001530.t004
mtDNA in Multiple Sclerosis
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of the SNP in the Caucasian populations illustrates the point. So
far, the prevalence of the nt13708A variant is known for 19
Caucasian populations, including 8 published populations
[5,9,14,21–24], 7 additional ones from this study and 4 own
characterized unpublished results. The prevalence varied dramat-
ically among populations, from 4.2% to 13.4% (Figure 2). A good
example is the three populations in the USA of European ancestry,
the prevalence varied from 4.8% to 11.2%.
In conclusion, we identified the nt13708A variant as susceptibility
allele for MS. These findings could contribute to defining the role of
the mitochondrial genome in MS pathogenesis. The mechanism
underlying the association will be investigated in the future.
Methods
Subjects
Six European MS cohorts were recruited for this study. Three of
them are well matched, in terms of age and geographic origin. These
are the Spanish cohort from Barcelona with 424 patients and 517
unrelated healthy controls, the Norwegian cohort from Bergen with
390 patients and 190 unrelated healthy controls as well as a German
cohort ( Germany I) from the Wu¨rzburg area with 285 patients and
382 unrelated healthy controls. The other three cohorts are not
ideally matched. Those , include the cohorts from Finland, Germany
(Germany II) and Sardinia. Population demographics of these three
cohorts are summarized in Table 3. In total, 5,209 individuals (2,582
controls and 2,639 MS cases) were recruited for this study. All MS
patients were classified according to the Poser criteria[31]. This
study was approved by the local Ethical Committee.
mtDNA genotyping
Seven common potentially functional mtDNA SNPs were
selected for the association study, including 4 non-synonymous
SNPs within protein coding region, 1 SNP within rRNA gene and
2 SNP within the control region. Genomic DNA was isolated from
peripheral blood cells, using standard methods. All the samples
were genotyped using the PCR-RFLP method with the exception
Table 5. Association of nt13708A variant with MS in Finnish sub-cohorts
Finland I 1 Finland II j
Frequency OR (95% CI) Frequency OR (95% CI)
Patient Control Patient Control
Non-age matched, controls younger* - - - 0.059 (n = 730) 0.033 (n = 122) 1.84 (0.65–5.19)
Non-age matched, controls older ** 0.102 (n = 206) 0.071 (n = 435) 1.48 (0.83–2.64) 0.059 (n = 730) 0.056 (n = 413) 1.06 (0.63–1.77)
1, Southern Ostrobothnia region;
j, Finland except Southern Ostrobothnia region.
*, the controls in Finland II cohort consist of 122 unrelated controls.
**For the Finland I cohort, the controls consists of 70 fathers of the patients (69.16 11.0 years) and 365 unrelated controls (59.7618.7 years) which are significantly
higher than patients (46.3611.7 years). For the Finland II cohort, controls consist of 295 fathers of the patients (66.869.5 years) and 108 fathers of the unrelated
controls.
doi:10.1371/journal.pone.0001530.t005
Figure 2. The prevalence of the nt13708 G/A polymorphism in Caucasian populations. The data are collected form 19 Caucasian
population, including 6 published (closed square), 8 in this study (closed cycle) and 5 unpublished (open cycle). The locations are indicated on the
map for the European populations. For the three USA populations, the location were indicated as the text. The prevalence of the mutation are
presented as the percentage of the minor allele.
doi:10.1371/journal.pone.0001530.g002
mtDNA in Multiple Sclerosis
PLoS ONE | www.plosone.org 5 February 2008 | Volume 3 | Issue 2 | e1530
of samples from Finnish cohort. The PCR amplification primers
and restriction endonucleases used for the SNPs genotyping are
summarized in supplementary Table S1. Amplification conditions
are as follows: 95uC for 5 min, followed by 2 cycles of 94uC for
30 s, 57uC for 1 min, 72uC for 1 min, then another 36 cycles of
94uC for 30 s, 55uC for 1 min, 72uC for 1 min, and a final
extension at 72uC for 7 min. The reactions were performed using
GeneAmp PCR System 9700 cycler. 10 ml PCR products were
digested by 1 u restriction endonuclease respectively at 37uC
overnight. mtDNA SNPs were genotyped according to the size of
the PCR products after the digestion. The SNP assay used to
genotype the Finnish cohort was designed using SpectroDE-
SIGNER (Sequenom), and the PCR and extension reactions were
done as specified by the manufacturer. Genotypes were automat-
ically called with the SpectroCALLER software (Sequenom), and
manually checked as described in Silander et al [32].
mtDNA sequencing and phylogenic analysis
The mtDNA were sequenced using microarray-based sequenc-
ing approach. The GeneChipH Human Mitochondrial Resequen-
cing Array 2.0 were obtained from Affymetrix (Affymetrix, Inc.
U.S.), with a sequence capacity of 16,535 bp (nt13 to nt16557).
Genomic DNA with a concentration of 20ng/ul were used for the
sequencing. PCR amplification, DNA fragmentation, labeling and
chip hybridization were performed according Affymetrix Custom-
Seq Resequencing protocol. Fluorescent signals were collected by
laser scan (GeneChipH Scanner 3000), and the data were analysed
using GeneChipH Operating Software (GOS) and GeneChipH
Sequence Analysis Software (GSEQ). The average call rate was
95.87 %. The mtDNA phylogenetic anlysis was performed using
ClustalW software. To prevent the negative effect of the sites
without call, we constructed the phylogenetic tree with only the
polymorphic sites.
Statistical analysis
We performed the association analysis for the case-cohort study
using Comprehensive Meta-analysis Version 2 software (http://
www.meta-analysis.com). For the individual MS cohorts, we
calculated OR values with 95% CI and two-tailed P values using
2-by-2 contingency tables. We performed Mantel-Haenszel meta-
analysis using a fixed model to calculate the OR and P values for
the combined cohorts [33]. A P value of ,0.05 was considered
significant.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0001530.s001 (0.02 MBXLS)
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